JP2016516800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516800A5 JP2016516800A5 JP2016508192A JP2016508192A JP2016516800A5 JP 2016516800 A5 JP2016516800 A5 JP 2016516800A5 JP 2016508192 A JP2016508192 A JP 2016508192A JP 2016508192 A JP2016508192 A JP 2016508192A JP 2016516800 A5 JP2016516800 A5 JP 2016516800A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- egfr antibody
- fucose
- cancer
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002108.2 | 2013-04-22 | ||
| EP13002106.6 | 2013-04-22 | ||
| EP13002106 | 2013-04-22 | ||
| EP13002108 | 2013-04-22 | ||
| PCT/EP2014/058118 WO2014173886A1 (en) | 2013-04-22 | 2014-04-22 | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516800A JP2016516800A (ja) | 2016-06-09 |
| JP2016516800A5 true JP2016516800A5 (cg-RX-API-DMAC7.html) | 2017-05-25 |
Family
ID=50729450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016508192A Withdrawn JP2016516800A (ja) | 2013-04-22 | 2014-04-22 | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 |
Country Status (13)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
| JP2019508380A (ja) * | 2016-01-10 | 2019-03-28 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｅｇｆｒに対するグリコシル化キメラ抗体での癌の処置のための改善された安全性 |
| JP6701382B2 (ja) | 2016-04-27 | 2020-05-27 | グリーン・クロス・コーポレイションＧｒｅｅｎ Ｃｒｏｓｓ Ｃｏｒｐ． | 上皮成長因子受容体に特異的に結合する抗体を有効成分として含む、癌の転移を抑制するための医薬組成物 |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| EP3484520A4 (en) | 2016-07-13 | 2020-07-29 | Reform Biologics, LLC | STABILIZING EXCIPIENTS FOR THERAPEUTIC PROTEIN FORMULATIONS |
| KR101884614B1 (ko) | 2016-10-11 | 2018-08-02 | 신일제약주식회사 | Fab 단편 및 이의 용도 |
| JP2020512382A (ja) * | 2017-03-29 | 2020-04-23 | グリコトープ ゲーエムベーハー | Ｐｄ−ｌ１抗体およびｔａ−ｍｕｃ１抗体 |
| CN110650976B (zh) * | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| WO2018219956A1 (en) * | 2017-05-29 | 2018-12-06 | Gamamabs Pharma | Cancer-associated immunosuppression inhibitor |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| WO2020100969A1 (ja) * | 2018-11-14 | 2020-05-22 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN112300278A (zh) * | 2019-07-25 | 2021-02-02 | 上海交通大学 | 抗人egfr嵌合抗体及其制备方法和用途 |
| EP4139357A1 (en) * | 2020-04-24 | 2023-03-01 | Merus N.V. | Treatment of cancers with an antibody that binds lgr5 and egfr |
| CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
| US20230250176A1 (en) * | 2022-02-09 | 2023-08-10 | Dragonfly Therapeutics, Inc. | Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| PT1176195E (pt) | 1999-04-09 | 2013-07-18 | Kyowa Hakko Kirin Co Ltd | Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico |
| EP1522590B1 (en) | 2000-06-28 | 2009-08-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| KR101569300B1 (ko) * | 2005-02-07 | 2015-11-13 | 로슈 글리카트 아게 | Ｅｇｆｒ 에 결합하는 항원 결합 분자, 이를 코딩하는 벡터, 및 그의 용도 |
| KR101603632B1 (ko) | 2006-09-10 | 2016-03-16 | 글리코토페 게엠베하 | 항체 발현을 위한 골수성 백혈병 기원의 인간 세포의 용도 |
| WO2011101328A2 (en) * | 2010-02-18 | 2011-08-25 | Roche Glycart Ag | Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor |
| WO2012020059A1 (en) * | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Humanized egfr antibodies |
| BR112013003095B1 (pt) * | 2010-08-10 | 2023-03-28 | Glycotope Gmbh | Método para controle da meia-vida em circulação de um anticorpo ou um fragmento ou derivado funcional do mesmo, composições de anticorpo, seu usos e seus métodos de produção |
-
2014
- 2014-04-22 US US14/784,470 patent/US20160068609A1/en not_active Abandoned
- 2014-04-22 MX MX2015014773A patent/MX2015014773A/es unknown
- 2014-04-22 AU AU2014257650A patent/AU2014257650A1/en not_active Abandoned
- 2014-04-22 JP JP2016508192A patent/JP2016516800A/ja not_active Withdrawn
- 2014-04-22 SG SG11201507743XA patent/SG11201507743XA/en unknown
- 2014-04-22 BR BR112015025955A patent/BR112015025955A2/pt not_active IP Right Cessation
- 2014-04-22 EA EA201591977A patent/EA201591977A1/ru unknown
- 2014-04-22 CA CA2908819A patent/CA2908819A1/en not_active Abandoned
- 2014-04-22 EP EP14724007.1A patent/EP2989126A1/en not_active Withdrawn
- 2014-04-22 KR KR1020157033309A patent/KR20150144804A/ko not_active Withdrawn
- 2014-04-22 WO PCT/EP2014/058118 patent/WO2014173886A1/en not_active Ceased
- 2014-04-22 CN CN201480021328.XA patent/CN105229030A/zh active Pending
-
2015
- 2015-09-30 ZA ZA2015/07246A patent/ZA201507246B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516800A5 (cg-RX-API-DMAC7.html) | ||
| AU2021202413B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors | |
| Agustoni et al. | EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis | |
| JP7122357B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| Henricks et al. | The use of combinations of monoclonal antibodies in clinical oncology | |
| JP2016516800A (ja) | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 | |
| Baldo | Monoclonal antibodies approved for cancer therapy | |
| TW201545759A (zh) | 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體 | |
| Jarboe et al. | Therapeutic human monoclonal antibodies against cancer | |
| JP2020522562A5 (cg-RX-API-DMAC7.html) | ||
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| WO2017205216A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| JPWO2022270524A5 (cg-RX-API-DMAC7.html) | ||
| Greillier et al. | Necitumumab for non-small cell lung cancer | |
| Ameri et al. | Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer | |
| CN104394887A (zh) | 采用具有低岩藻糖化的抗her2抗体的新治疗性疗法 | |
| CN110177807B (zh) | 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗 | |
| JP2012025694A (ja) | 癌治療剤 | |
| WO2022232503A1 (en) | Therapeutic and diagnostic methods and compositions for cancer | |
| Ramanathan | Alternative dosing schedules for cetuximab: a role for biweekly administration? | |
| CN116745322A (zh) | 使用抗岩藻糖基-gm1抗体的组合疗法 | |
| Rahman et al. | Monoclonal antibody: a cell specific immunotherapy to treat cancer | |
| Wan et al. | Progress of immune checkpoint inhibitors in gastric cancer | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 | |
| CN103768596A (zh) | 用于肿瘤治疗的组合产品、其用途及相关方法 |